Creating a new treatment to improve blood production in patients with specific blood disorders
Developing an inhibitor of EIF2AK1 to overcome ineffective erythropoiesis in myelodysplastic syndromes with ringed sideroblasts
This study is testing a new medication that could help improve blood cell production for patients with myelodysplastic syndromes and ringed sideroblasts, aiming to reduce anemia and the need for blood transfusions.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10726479 on NIH RePORTER |
What this research studies
This research focuses on developing a new small-molecule inhibitor that targets EIF2AK1, a protein involved in the regulation of blood cell production, specifically for patients with myelodysplastic syndromes characterized by ringed sideroblasts. The study aims to address the ineffective erythropoiesis, or blood cell production, that many patients experience, which often leads to severe anemia and the need for frequent blood transfusions. By inhibiting EIF2AK1, the researchers hope to enhance the differentiation of blood cells and reduce the dependency on transfusions. The research will involve testing this inhibitor in samples from patients with specific genetic mutations associated with their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myelodysplastic syndromes, particularly those with mutations in the SF3B1 gene and who experience severe anemia.
Not a fit: Patients without myelodysplastic syndromes or those who do not have the specific SF3B1 mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that improves blood production and reduces the need for blood transfusions in patients with myelodysplastic syndromes.
How similar studies have performed: Previous studies have shown promise in targeting similar pathways for improving blood production, but this specific approach is novel and has not been extensively tested.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Colla, Simona — University of Tx Md Anderson Can Ctr
- Study coordinator: Colla, Simona
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.